• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用uPA基因敲除和免疫缺陷异种移植联合模型,获得关于基质尿激酶型纤溶酶原激活剂(uPA)在实验性人类乳腺癌生长中重要性的直接证据。

Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.

作者信息

Frandsen T L, Holst-Hansen C, Nielsen B S, Christensen I J, Nyengaard J R, Carmeliet P, Brünner N

机构信息

The Fintsen Laboratory, Copenhagen University Hospital, Denmark.

出版信息

Cancer Res. 2001 Jan 15;61(2):532-7.

PMID:11212246
Abstract

Several studies have indicated an interaction between tumor cells and infiltrating stromal cells regarding the urokinase plasminogen activation (uPA) system. By developing combined uPA gene-disrupted and immunodeficient mice, we have studied the role of stromal uPA for the growth of the MDA-MB-435 BAG human tumor xenograft. Subcutaneous tumor growth and lung metastasis were compared between wild-type immunodeficient mice and mice with the combined deficiencies. Tumor growth was evaluated by volume measurements and plasma beta-galactosidase activity and metastasis was evaluated by counting lung surface metastases. Although no differences appeared in primary tumor take between the two groups of mice, a significant difference was observed in primary tumor growth, with tumors in uPA-/- mice growing significantly more slowly. In addition, a nonsignificant trend toward fewer lung metastases in uPA-/- mice was observed. The present data points to a critical role of stromal-derived uPA in the primary tumor growth of MDA-MB-435 BAG xenografts, whereas only a trend toward fewer lung metastases in uPA gene-disrupted mice was found.

摘要

多项研究表明,在尿激酶型纤溶酶原激活(uPA)系统方面,肿瘤细胞与浸润性基质细胞之间存在相互作用。通过培育uPA基因缺失与免疫缺陷相结合的小鼠,我们研究了基质uPA在MDA-MB-435 BAG人肿瘤异种移植瘤生长中的作用。比较了野生型免疫缺陷小鼠与联合缺陷小鼠的皮下肿瘤生长及肺转移情况。通过体积测量和血浆β-半乳糖苷酶活性评估肿瘤生长,通过计数肺表面转移灶评估转移情况。虽然两组小鼠在原发性肿瘤形成方面未出现差异,但在原发性肿瘤生长方面观察到显著差异,uPA基因敲除小鼠的肿瘤生长明显更缓慢。此外,观察到uPA基因敲除小鼠的肺转移有减少的趋势,但不显著。目前的数据表明,基质来源的uPA在MDA-MB-435 BAG异种移植瘤的原发性肿瘤生长中起关键作用,而在uPA基因敲除小鼠中仅发现肺转移有减少的趋势。

相似文献

1
Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.使用uPA基因敲除和免疫缺陷异种移植联合模型,获得关于基质尿激酶型纤溶酶原激活剂(uPA)在实验性人类乳腺癌生长中重要性的直接证据。
Cancer Res. 2001 Jan 15;61(2):532-7.
2
Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).可溶性尿激酶型纤溶酶原激活物受体(CD87)过表达可减少乳腺癌肿瘤生长及肺转移。
Cancer Gene Ther. 2000 Feb;7(2):292-9. doi: 10.1038/sj.cgt.7700144.
3
Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.降钙素抑制乳腺癌细胞的侵袭:尿激酶型纤溶酶原激活剂(uPA)及uPA受体的作用
Int J Oncol. 2006 Apr;28(4):807-14.
4
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.同基因乳腺癌模型中尿激酶的蛋白酶活性与肿瘤进展
J Natl Cancer Inst. 2006 Jun 7;98(11):756-64. doi: 10.1093/jnci/djj208.
5
Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer.miR-193b的下调有助于增强人乳腺癌中尿激酶型纤溶酶原激活剂(uPA)的表达以及肿瘤进展和侵袭。
Oncogene. 2009 Nov 5;28(44):3937-48. doi: 10.1038/onc.2009.245. Epub 2009 Aug 24.
6
Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.在缺乏尿激酶型纤溶酶原激活物基因或其抑制剂纤溶酶原激活物抑制剂-1的小鼠中,肿瘤发展受到抑制。
Cancer Res. 2000 Oct 15;60(20):5839-47.
7
The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.乳腺肿瘤组织基质中的尿激酶系统与乳腺癌细胞侵袭
Int J Oncol. 2009 Jan;34(1):15-23.
8
Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice.腺病毒介导的尿激酶型纤溶酶原激活剂/尿激酶型纤溶酶原激活剂受体拮抗剂递送可抑制小鼠体内血管生成依赖性肿瘤的生长和扩散。
Gene Ther. 1998 Aug;5(8):1105-13. doi: 10.1038/sj.gt.3300742.
9
Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.靶向人胰腺癌细胞中的尿激酶型纤溶酶原激活物受体可抑制c-Met和胰岛素样生长因子-I受体介导的迁移、侵袭以及小鼠原位肿瘤生长。
Cancer Res. 2005 Sep 1;65(17):7775-81. doi: 10.1158/0008-5472.CAN-05-0946.
10
Inhibition of human breast cancer cell invasion by siRNA against urokinase-type plasminogen activator.siRNA 抑制尿激酶型纤溶酶原激活物对人乳腺癌细胞侵袭的作用。
Cancer Invest. 2010 Aug;28(7):689-97. doi: 10.3109/07357901003735642.

引用本文的文献

1
Urokinase plasminogen activator as an anti-metastasis target: inhibitor design principles, recent amiloride derivatives, and issues with human/mouse species selectivity.尿激酶型纤溶酶原激活剂作为抗转移靶点:抑制剂设计原则、近期氨氯地平衍生物以及人/小鼠物种选择性问题
Biophys Rev. 2022 Jan 6;14(1):277-301. doi: 10.1007/s12551-021-00921-7. eCollection 2022 Feb.
2
Implications of prognosis-associated genes in pancreatic tumor metastasis: lessons from global studies in bioinformatics.预后相关基因在胰腺肿瘤转移中的意义:生物信息学全球研究的启示。
Cancer Metastasis Rev. 2021 Sep;40(3):721-738. doi: 10.1007/s10555-021-09991-1. Epub 2021 Sep 30.
3
FOXM1 functions collaboratively with PLAU to promote gastric cancer progression.
叉头框蛋白M1(FOXM1)与纤溶酶原激活物尿激酶型(PLAU)协同作用促进胃癌进展。
J Cancer. 2020 Jan 1;11(4):788-794. doi: 10.7150/jca.37323. eCollection 2020.
4
Decreased methylation in the SNAI2 and ADAM23 genes associated with de-differentiation and haematogenous dissemination in breast cancers.SNAI2 和 ADAM23 基因甲基化程度降低与乳腺癌去分化和血源性播散有关。
BMC Cancer. 2018 Sep 6;18(1):875. doi: 10.1186/s12885-018-4783-x.
5
D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR.尿激酶受体的 D2A 序列通过 αvβ3 整合素和 EGFR 诱导细胞生长。
Cell Mol Life Sci. 2018 May;75(10):1889-1907. doi: 10.1007/s00018-017-2718-3. Epub 2017 Nov 28.
6
BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer.BreastDefend™ 可预防三阴性人乳腺癌的原位动物模型中的乳腺癌向肺转移。
Oncol Rep. 2012 Oct;28(4):1139-45. doi: 10.3892/or.2012.1936. Epub 2012 Jul 26.
7
Proteinases and their inhibitors in liver cancer.肝癌中的蛋白酶及其抑制剂
World J Hepatol. 2009 Oct 31;1(1):28-34. doi: 10.4254/wjh.v1.i1.28.
8
Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy.基于结构的尿激酶与其受体相互作用中物种选择性的工程改造:对临床前癌症治疗的启示。
J Biol Chem. 2010 Apr 2;285(14):10982-92. doi: 10.1074/jbc.M109.093492. Epub 2010 Feb 4.
9
Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by host-derived urokinase-type plasminogen activator.组织金属蛋白酶抑制剂-1 诱导的散发性肝转移是由宿主来源的尿激酶型纤溶酶原激活物介导的。
J Cell Mol Med. 2010 Dec;14(12):2760-70. doi: 10.1111/j.1582-4934.2009.00951.x.
10
Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis.骨髓来源的组织蛋白酶K在骨转移中裂解富含半胱氨酸的酸性分泌蛋白(SPARC)。
Am J Pathol. 2009 Sep;175(3):1255-69. doi: 10.2353/ajpath.2009.080906. Epub 2009 Aug 21.